Knock it off: Biosimilars are not a 'knockoff' drug
I like nice Nikes. Some can get pricey. Would I’d never wear a knockoff? No.
Let’s start at square one by asking: why don’t we just call biosimilars generics? Or bio-generics?
The public doesn’t know what a biosimilar is, but generics are standard fare: cheaper versions pricey drugs that work. Biosimilars promise to bring the cost of healthcare down and access to crucial medicines up, just like generics. And now, the FDA just gave a vigorous endorsement to two franchise-busting biosimilars on all indications as the original drug. These medicines look every bit as good as branded Humira and Enbrel.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.